Quick Answer
Indivior Pharmaceuticals, Inc. reported Stockholders Equity of -$98.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$98.00M | +70.9% |
| 2024 | -$337.00M | -83.2% |
| 2023 | -$184.00M | -1126.7% |
| 2022 | -$15.00M | -112.4% |
| 2021 | $121.00M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$207.00M | +33.2% | +19.5% |
| June 30, 2025 | -$257.00M | +8.5% | +9.8% |
| March 31, 2025 | -$285.00M | -77.0% | +15.4% |
| December 31, 2024 | -$337.00M | -83.2% | -8.7% |
| September 30, 2024 | -$310.00M | — | -10.3% |
| June 30, 2024 | -$281.00M | — | -74.5% |
| March 31, 2024 | -$161.00M | — | +12.5% |
| December 31, 2023 | -$184.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +70.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Indivior Pharmaceuticals, Inc.’s stockholders equity has declined by 181.0% (from $121.00 million to -$98.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: